Chief Medical Officer Medtronic Diabetes Washington, District of Columbia, United States
The real-world use of the MiniMedTM 780G (MM780G) advanced hybrid closed loop system is growing to include thousands of individuals who include children, adolescents and adults across a wide range of glycemic control. We report on real-world performance of the MM780G in 60,000+ individuals using the system for 12 months. Across age groups and over time, most CGM metrics exceeded ADA recommended targets and was further improved with 100 mg/dL GT and 2 hours active insulin time settings.
.jpg "Robert Vigersky, MD (he/him/his) photo")